


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A compound selected from the group consisting of compounds of formula (I)




wherein

- U is O or a lone pair;
- V is O, S, -CH₂-, -CH=CH-, or -C≡C-;
- W is CO, COO, CONR¹, CSO, CSNR¹, SO₂, or SO₂NR¹;
- m and n are each integers from 0 to 7, with the provisos that m+n is 0 to 7 and m is not 0 when V is O or S;
- A¹ is H, lower-alkyl, hydroxy-lower-alkyl, or lower-alkenyl and
- A² is lower-alkyl, cycloalkyl, cycloalkyl-lower-alkyl, or lower-alkenyl, optionally substituted by R², or
- A¹ and A² bond together to form -A¹-A²-, wherein -A¹-A²- is lower-alkylene or lower-alkenylene, optionally substituted by R², in which one -CH₂- group of -A¹-A²- is optionally replaced by NR³, S, or O;
- A³ and A⁴ are each hydrogen or lower-alkyl, or
- A³ and A⁴ bond together to form -A³-A⁴-, wherein -A³-A⁴- is -(CH₂)₂₋₅- optionally mono- or multiply-substituted by lower-alkyl;

A^5 is H, lower-alkyl, lower-alkenyl, or aryl-lower-alkyl;
 A^6 is lower-alkyl, cycloalkyl, aryl, aryl-lower-alkyl, heteroaryl, heteroaryl-lower-alkyl, lower-alkoxy-carbonyl-lower-alkyl;
 R^2 is hydroxy, hydroxy-lower-alkyl, lower-alkoxy, lower-alkoxycarbonyl, $N(R^4, R^5)$, or thio-lower-alkoxy;
 R^1 , R^3 , R^4 and R^5 independently from each other are hydrogen or lower-alkyl; and
when A^1 is not bonded to A^2 and A^3 is not bonded to A^4 , A^1 and A^3 optionally bond together to form $-A^1-A^3-$, wherein $-A^1-A^3-$ is lower-alkylene or lower-alkenylene, optionally substituted by R^2 , in which one $-CH_2-$ group of $-A^1-A^3-$ is optionally replaced by NR^3 , S, or O;
pharmaceutically acceptable salts of the compounds of formula (I), and
pharmaceutically acceptable esters of the compounds of formula (I).

2. (Original) The compound according to claim 1, wherein A^3 and A^4 are not bonded together.
3. (Original) The compound according to claim 1, selected from the group consisting of compounds of formula (Ia):




wherein U, V, W, m, n, A^1 , A^2 , A^3 , A^4 , A^5 and A^6 are as defined in claim 1;
pharmaceutically acceptable salts of the compounds of formula (Ia); and
pharmaceutically acceptable esters of the compounds of formula (Ia).

4. (Original) The compound according to claim 1, wherein U is a lone pair.
5. (Original) The compound according to claim 4, wherein V is O.
6. (Original) The compound according to claim 4, wherein V is $\text{-CH}_2\text{-}$.
7. (Original) The compound according to claim 4, wherein V is -C=C- .
8. (Original) The compound according to claim 4, wherein V is $\text{-C}\equiv\text{C-}$.
9. (Original) The compound according to claim 4, wherein W is CO, COO, CONR^1 , CSNR^1 , SO_2 or SO_2NR^1 and R^1 is hydrogen.
10. (Original) The compound according to claim 9, wherein W is COO or SO_2 .
11. (Original) The compound according to claim 10, wherein n is 0.
12. (Original) The compound according to claim 10, wherein n is 1.
13. (Original) The compound according to claim 10, wherein m is 1 to 6.
14. (Original) The compound according to claims 10, wherein m is 0 and V is -C=C- or $\text{-C}\equiv\text{C-}$.
15. (Original) The compound according to claim 10, wherein A^1 is H, methyl, ethyl, isopropyl, 2-hydroxy-ethyl, or 2-propenyl.

16. (Original) The compound according to claim 10, wherein A^2 is lower-alkyl, cycloalkyl-lower-alkyl, or lower-alkenyl, optionally substituted with R^2 , wherein R^2 is hydroxy, methoxy, or ethoxycarbonyl.
17. (Original) The compound according to claim 16, wherein A^2 is methyl, ethyl, 2-hydroxyethyl, 2-propenyl, propyl or isopropyl.
18. (Original) The compound according to claim 10, wherein A^1 and A^2 are bonded together.
19. (Original) The compound according to claim 18, wherein $-A^1-A^2-$ is lower-alkylene or lower-alkenylene, optionally substituted by R^2 , in which one $-CH_2-$ group of $-A^1-A^2-$ can optionally be replaced by O, wherein R^2 is hydroxy or 2-hydroxyethyl.
20. (Original) The compound according to claim 19, wherein $-A^1-A^2-$ is $-(CH_2)_5-$.
21. (Original) The compound according to claim 10, wherein A^3 is hydrogen.
22. (Original) The compound according to claim 10, wherein A^4 is hydrogen.
23. (Original) The compound according to claim 10, wherein A^3 and A^4 are bonded together to form $-A^3-A^4-$, and $-A^3-A^4-$ is $-(CH_2)_2-$.
24. (Original) The compound according to claim 10, wherein A^5 is H, lower-alkyl, lower-alkenyl, or benzyl optionally substituted with halogen.

25. (Original) The compounds according to claim 24, wherein A⁵ is methyl or ethyl.
26. (Original) The compound according to claim 25, wherein A⁶ is lower-alkyl, cycloalkyl, phenyl, naphthyl, phenyl-lower-alkyl, pyridyl, indolyl, indoliny, thienyl, thienyl-methylene, furyl-methylene, benzodioxyl, chinolyl, isoxazolyl, or imidazolyl, optionally substituted by one or more substituents selected from the group consisting of lower-alkyl, lower-alkoxy, lower-alkylcarbonyl, lower-alkoxycarbonyl, fluorine, chlorine, bromine, CN, CF₃, NO₂, or N(R⁶,R⁷), wherein R⁶ and R⁷ independently from each other are hydrogen or lower-alkyl.
27. (Original) The compound according to claim 26, wherein A⁶ is phenyl optionally substituted by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, and CF₃.
28. (Original) The compound according to claim 27, wherein A⁶ is 4-chloro-phenyl, 4-bromo-phenyl, or 4-trifluoromethyl-phenyl.
29. (Original) The compound according to claim 28, wherein A¹ is H, lower alkyl or hydroxy-lower alkyl and A² is lower alkyl, hydroxy-lower alkyl or lower alkenyl.
30. (Original) The compound according to claim 29, wherein A³ and A⁴ are hydrogen.
31. (Original) The compound according to claim 30, wherein V is O.
32. (Original) The compound according to claim 30, wherein V is S.

33. (Original) The compound according to claim 32, selected from the group consisting of trans-{4-[2-(allyl-methyl-amino)-ethylsulfanylmethyl]-cyclohexyl}-methyl-carbamic acid 4-chloro-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.
34. (Original) The compound according to claim 30, wherein V is $-\text{CH}_2-$.
35. (Original) The compound according to claim 30, wherein V is $-\text{C}=\text{C}-$.
36. (Original) The compound according to claim 30, wherein V is $-\text{C}\equiv\text{C}-$.
37. (Currently amended) A compound selected from the group consisting of compounds of formula (Ib):



wherein

V is O, S, $-\text{CH}_2-$, $-\text{CH}=\text{CH}-$, or $-\text{C}\equiv\text{C}-$;

W is COO or SO_2 ;

p is an integer from 0 to 7, with the proviso that p is not 0 when V is O or S;

A^{11} is H, lower-alkyl, or hydroxy-lower-alkyl and

A^{12} is lower-alkyl, hydroxy-lower alkyl, or lower-alkenyl, or

A^{11} and A^{12} bond together to form $[-A^1-A^2-]_n-A^{11}-A^{12}-$, wherein $[-A^1-A^2-]_n-A^{11}-A^{12}-$ is lower-alkylene;

A^{13} and A^{14} are each hydrogen or bond together to form $[-A^3-A^4-]_m-A^{13}-A^{14}-$, wherein $[-A^3-A^4-]_m-A^{13}-A^{14}-$ is $-(CH_2)_{2-5}$;

A^{15} is lower-alkyl; and

A^{16} is halogen or trifluoromethyl;

pharmaceutically acceptable salts of the compounds of formula (Ib), and

pharmaceutically acceptable esters of the compounds of formula(Ib).

38. (Currently amended) The ~~compound~~ compound according to claim 37, wherein A^{11} is H, lower-alkyl, or hydroxy-lower-alkyl and A^{12} is lower-alkyl, hydroxy-lower alkyl, or lower-alkenyl.

39. (Original) The compound according to claim 38, selected from the group consisting of trans-N-{4-[2-(1-dimethylamino-cyclopropyl)-ethoxy]-cyclohexyl}-N-methyl-4-trifluoromethyl-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

40. (Original) The compound according to claim 37, whereon A^{13} and A^{14} are hydrogen.

41. (Original) The compound according to claim 40, selected from the group consisting of trans-4-bromo-N-methyl-N-[4-(2-piperidin-1-yl-ethoxy)-cyclohexyl]-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

42. (Original) The compound according to claim 40, selected from the group consisting of trans-methyl-[4-(4-piperidin-1-yl-butyl)-cyclohexyl]-carbamic acid 4-bromo-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

43. (Original) The compound according to claim 40, selected from the group consisting of trans-N-methyl-N-[4-(4-piperidin-1-yl-butyl)-cyclohexyl]-4-trifluoromethyl-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

44. (Original) The compound according to claim 40, selected from the group consisting of trans-methyl-[4-(5-piperidin-1-yl-pentyl)-cyclohexyl]-carbamic acid 4-chloro-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

45. (Original) The compound according to claim 40, wherein A¹¹ is H, lower-alkyl, or hydroxy-lower-alkyl and A¹² is lower-alkyl, hydroxy-lower alkyl, or lower-alkenyl.

46. (Original) The compound according to claim 45, wherein V is O.

47. (Original) The compound according to claim 46, wherein W is COO.

48. (Original) The compound according to claim 47, selected from the group consisting of trans-{4-[6-(allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-carbamic acid 4-chloro-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

49. (Original) The compound according to claim 47, selected from the group consisting of {4-trans-[4-(allyl-methyl-amino)-butoxy]-cyclohexyl}-methyl-carbamic acid 4-trifluoromethyl-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

50. (Original) The compound according to claim 47, selected from the group consisting of trans-(4-{4-[ethyl-(2-hydroxy-ethyl)-amino]-butoxy}-cyclohexyl)-methyl-carbamic acid 4-trifluoromethyl-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

51. (Original) The compound according to claim 47, selected from the group consisting of trans-[4-(4-dimethylamino-butoxy)-cyclohexyl]-methyl-carbamic acid 4-trifluoromethyl-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

52. (Original) The compound according to claim 47, selected from the group consisting of trans-{4-[4-(allyl-methyl-amino)-butoxy]-cyclohexyl}-methyl-carbamic acid 4-chloro-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

53. (Original) The compound according to claim 46, wherein W is SO₂.

54. (Original) The compound according to claim 53, selected from the group consisting of trans-N-[4-(3-allylamino-propoxy)-cyclohexyl]-N-methyl-4-trifluoromethyl-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

55. (Original) The compound according to claim 53, selected from the group consisting of trans-N-[4-(6-diethylamino-hexyloxy)-cyclohexyl]-N-methyl-4-trifluoromethyl-

benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

56. (Original) The compound according to claim 53, selected from the group consisting of trans-N-[4-(4-dimethylamino-butoxy)-cyclohexyl]-N-ethyl-4-trifluoromethyl-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

57. (Original) The compound according to claim 53, selected from the group consisting of trans-N-ethyl-N-(4-{4-[(2-hydroxy-ethyl)-methyl-amino]-butoxy}-cyclohexyl)-4-trifluoromethyl-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

58. (Original) The compound according to claim 53, selected from the group consisting of trans-N-(4-{4-[bis-(2-hydroxy-ethyl)-amino]-butoxy}-cyclohexyl)-N-ethyl-4-trifluoromethyl-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

59. (Original) The compound according to claim 53, selected from the group consisting of trans-4-bromo-N-[4-(2-diisopropylamino-ethoxy)-cyclohexyl]-N-methyl-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

60. (Original) The compound according to claim 45, wherein V is S.

61. (Original) The compound according to claim 60, wherein W is COO.

62. (Original) The compound according to claim 60, wherein W is SO₂.
63. (Original) The compound according to claim 45, wherein V is -CH₂-.
64. (Original) The compound according to claim 63, wherein W is COO.
65. (Original) The compound according to claim 64, wherein A¹¹ is H.
66. (Original) The compound according to claim 65, selected from the group consisting of trans-methyl-[4-(5-methylamino-pentyl)-cyclohexyl]-carbamic acid 4-trifluoromethyl-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.
67. (Original) The compound according to claim 64, wherein A¹¹ is methyl.
68. (Original) The compound according to claim 67, selected from the group consisting of trans-{4-[5-(allyl-methyl-amino)-pentyl]-cyclohexyl}-methyl-carbamic acid 4-trifluoromethyl-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.
69. (Original) The compound according to claim 67, selected from the group consisting of trans-{4-[5-(allyl-methyl-amino)-pentyl]-cyclohexyl}-methyl-carbamic acid 4-bromo-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

70. (Original) The compound according to claim 67, selected from the group consisting of trans-{4-[5-(allyl-methyl-amino)-pentyl]-cyclohexyl}-methyl-carbamic acid 4-chloro-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

71. (Original) The compound according to claim 67, selected from the group consisting of trans-{4-[4-(allyl-methyl-amino)-butyl]-cyclohexyl}-methyl-carbamic acid 4-chloro-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

72. (Original) The compound according to claim 64, wherein A¹¹ is ethyl.

73. (Original) The compound according to claim 72, selected from the group consisting of trans-(4-{5-[ethyl-(2-hydroxy-ethyl)-amino]-pentyl}-cyclohexyl)-methyl-carbamic acid 4-trifluoromethyl-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

74. (Original) The compound according to claim 72, selected from the group consisting of trans-(4-{5-[ethyl-(2-hydroxy-ethyl)-amino]-pentyl}-cyclohexyl)-methyl-carbamic acid 4-bromo-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

75. (Original) The compound according to claim 72, selected from the group consisting of trans-(4-{3-[ethyl-(2-hydroxy-ethyl)-amino]-propyl}-cyclohexyl)-methyl-carbamic acid 4-chloro-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

76. (Original) The compound according to claim 63, wherein W is SO₂.
77. (Original) The compound according to claim 76, selected from the group consisting of trans-N-{4-[5-(allyl-methyl-amino)-pentyl]-cyclohexyl}-N-methyl-4-trifluoromethyl-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.
78. (Original) The compound according to claim 76, selected from the group consisting of trans-N-(4-{5-[ethyl-(2-hydroxy-ethyl)-amino]-pentyl}-cyclohexyl)-N-methyl-4-trifluoromethyl-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.
79. (Original) The compound according to claim 45, wherein V is -C=C-.
80. (Original) The compound according to claim 79, wherein W is COO.
81. (Original) The compound according to claim 79, wherein W is SO₂.
82. (Original) The compound according to claim 81, selected from the group consisting of trans-(1E)-N-methyl-N-{4-[3-(methyl-propyl-amino)-propenyl]-cyclohexyl}-4-trifluoromethyl-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.
83. (Original) The compound according to claim 81, selected from the group consisting of trans-(1E)-N-(4-{3-[ethyl-(2-hydroxy-ethyl)-amino]-propenyl}-cyclohexyl)-N-methyl-4-trifluoro-

methyl-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

84. (Original) The compound according to claim 45, wherein V is $-C\equiv C-$.

85. (Original) The compound according to claim 84, wherein W is COO.

86. (Original) The compound according to claim 85, selected from the group consisting of trans-{4-[3-(allyl-methyl-amino)-prop-1-ynyl]-cyclohexyl}-methyl-carbamic acid 4-chloro-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

87. (Original) The compound according to claim 85, selected from the group consisting of trans-(4-{5-[ethyl-(2-hydroxy-ethyl)-amino]-pent-1-ynyl}-cyclohexyl)-methyl-carbamic acid 4-chloro-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

88. (Original) The compound according to claim 85, selected from the group consisting of trans-methyl-{4-[3-(methyl-propyl-amino)-prop-1-ynyl]-cyclohexyl}-carbamic acid 4-chloro-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.


89. (Original) The compound according to claim 84, wherein W is SO₂.

90. (Original) The compound according to claim 89, selected from the group consisting of trans-N-[4-(4-dimethylamino-but-1-ynyl)-cyclohexyl]-N-methyl-4-trifluoromethyl-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

91. (Original) The compound according to claim 89, selected from the group consisting of trans-N-methyl-N-{4-[4-(methyl-propyl-amino)-but-1-ynyl]-cyclohexyl}-4-trifluoromethyl-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

92. (Original) The compound according to claim 89, selected from the group consisting of trans-N-(4-{4-[ethyl-(2-hydroxy-ethyl)-amino]-but-1-ynyl}-cyclohexyl)-N-methyl-4-trifluoromethyl-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

93. (Original) A process for the manufacture of a compound according to claim 1, comprising reacting a compound of formula (II):



wherein

A^5 is as defined in claim 1,

Z is a group $(A^1, A^2)N-C(A^3, A^4)-(CH_2)_m-V-(CH_2)_n$ or $HO-(CH_2)_n$, wherein A^1, A^2, A^3, A^4, V , m and n are defined as in claim 1,

with $ClSO_2-A^6, ClCOO-A^6, ClCSO-A^6, OCN-A^6, SCN-A^6, HOOC-A^6$, or $ClSO_2NR^1-A^6$, wherein A^6 is as defined in claim 1.

94. (Original) A pharmaceutical composition comprising a compound according to claim 1 and at least one of a pharmaceutically acceptable carrier or a pharmaceutically acceptable adjuvant.

95. (New) The compound according to claim 36, selected from the group consisting of trans-methyl-{4-[5-(methyl-propyl-amino)-pent-1-ynyl]-cyclohexyl}-carbamic acid 4-chloro-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

96. (New) A pharmaceutical composition comprising a compound according to claim 95 and at least one of a pharmaceutically acceptable carrier or a pharmaceutically acceptable adjuvant.

97. (New) The compound according to claim 85, selected from the group consisting of trans-methyl-{4-[5-(methyl-propyl-amino)-pent-1-ynyl]-cyclohexyl}-carbamic acid 4-chloro-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

98. (New) A pharmaceutical composition comprising a compound according to claim 97 and at least one of a pharmaceutically acceptable carrier or a pharmaceutically acceptable adjuvant.